share_log

TC BioPharm | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(9.99%),Steven Boyd(9.99%)

TC BioPharm | SC 13G/A:超過5%持股股東披露文件(修正)-Armistice Capital, LLC(9.99%),Steven Boyd(9.99%)

SEC announcement ·  02/14 14:39
Moomoo AI 已提取核心訊息
On December 31, 2023, Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a shared voting and dispositive power over 105,938 American Depositary Shares of TC BioPharm (Holdings) PLC, which represents 9.99% of the class. Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., and Steven Boyd, as the managing member of Armistice Capital, are deemed to beneficially own the shares held by the Master Fund. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, indicating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The filing was certified by Steven Boyd on February 14, 2024.
On December 31, 2023, Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a shared voting and dispositive power over 105,938 American Depositary Shares of TC BioPharm (Holdings) PLC, which represents 9.99% of the class. Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., and Steven Boyd, as the managing member of Armistice Capital, are deemed to beneficially own the shares held by the Master Fund. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, indicating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The filing was certified by Steven Boyd on February 14, 2024.
2023年12月31日,停戰資本有限責任公司和史蒂芬·博伊德向美國證券交易委員會提交了經修訂的附表13G/A,表示對佔該類別9.99%的TC BioPharm(控股)PLC的105,938股美國存托股票擁有共同的投票權和處置權。作爲停戰資本主基金有限公司投資經理的停戰資本和作爲停戰資本管理成員的史蒂芬·博伊德被視爲受益擁有主基金持有的股份。該文件是根據1934年《證券交易法》第13d-1(b)條提交的,表明股票是在正常業務過程中收購的,不是爲了改變或影響發行人的控制權。該文件於2024年2月14日由史蒂芬·博伊德認證。
2023年12月31日,停戰資本有限責任公司和史蒂芬·博伊德向美國證券交易委員會提交了經修訂的附表13G/A,表示對佔該類別9.99%的TC BioPharm(控股)PLC的105,938股美國存托股票擁有共同的投票權和處置權。作爲停戰資本主基金有限公司投資經理的停戰資本和作爲停戰資本管理成員的史蒂芬·博伊德被視爲受益擁有主基金持有的股份。該文件是根據1934年《證券交易法》第13d-1(b)條提交的,表明股票是在正常業務過程中收購的,不是爲了改變或影響發行人的控制權。該文件於2024年2月14日由史蒂芬·博伊德認證。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息